ReviewAntibiotics (Basel, Switzerland)2021
Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation.
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Sarecycline for moderate to severe acne: a promising narrow-spectrum antibacterial drug.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Antimicrobial Gelatin Methacryloyl (GelMA)/Bioactive Glass Dental Adhesives.Journal of functional biomaterials · 2026Article
- Distinct Osteogenic Profiles of Tetracyclines from Different Generations in an Ex Vivo Embryonic Chick Femur Model.International journal of molecular sciences · 2026Article
- Efficacy and Safety of Sarecycline in Chinese Patients with Moderate-to-Severe Acne Vulgaris: Randomized Phase 3 Clinical Trial with Open-Label Follow-Up.Dermatology and therapy · 2025Article
- Article
- Combinations of Antibiotics Effective against Extensively- and Pandrug-ResistantMicroorganisms · 2024Article
- Optimizing Bothropstoxin-I-Derived Peptides: Exploring the Antibacterial Potential of p-BthW.ACS omega · 2024Article
- A Retrospective Review of a Cohort of Patients with Periorificial Dermatitis Treated with Sarecycline.The Journal of clinical and aesthetic dermatology · 2024Article
- Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea.Frontiers in immunology · 2024Review
- Bidirectional Interaction between Tetracyclines and Gut Microbiome.Antibiotics (Basel, Switzerland) · 2023Review
- Unveiling the Osteogenic Potential of Tetracyclines: A Comparative Study in Human Mesenchymal Stem Cells.Cells · 2023Article
- Oral Tetracycline-Class Drugs in Dermatology: Impact of Food Intake on Absorption and Efficacy.Antibiotics (Basel, Switzerland) · 2023Review
- Sarecycline inhibits protein translation in Cutibacterium acnes 70S ribosome using a two-site mechanism.Nucleic acids research · 2023Article
- Microbiomes in Acne Vulgaris and Their Susceptibility to Antibiotics in Indonesia: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2023Review
- Effect of Sarecycline on the Acne Symptom and Impact Scale and Concerns in Moderate-to-Severe Truncal Acne in Open-Label Pilot Study.Antibiotics (Basel, Switzerland) · 2023Article
- Study on Antibacterial Activity and Mechanism of Improved Dian Dao San AgainstInfection and drug resistance · 2023Article
- Role of the skin microbiota and intestinal microbiome in rosacea.Frontiers in microbiology · 2023Review
- Cryogenic 3D Printing of w/o Pickering Emulsions Containing Bifunctional Drugs for Producing Hierarchically Porous Bone Tissue Engineering Scaffolds with Antibacterial Capability.International journal of molecular sciences · 2022Article
- Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris.Antibiotics (Basel, Switzerland) · 2022Article
- Sarecycline Demonstrates Clinical Effectiveness against Staphylococcal Infections and Inflammatory Dermatoses: Evidence for Improving Antibiotic Stewardship in Dermatology.Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
Abstract
Prolonged broad-spectrum antibiotic use is more likely to induce bacterial resistance and dysbiosis of skin and gut microflora. First and second-generation tetracycline-class antibiotics have similar broad-spectrum antibacterial activity. Targeted tetracycline-class antibiotics are needed to limit antimicrobial resistance and improve patient outcomes. Sarecycline is a narrow-spectrum, third-generation tetracycline-class antibiotic Food and Drug Administration (FDA)-approved for treating moderate-to-severe acne. In vitro studies demonstrated activity against clinically relevant Gram-positive bacteria but reduced activity against Gram-negative bacteria. Recent studies have provided insight into how the structure of sarecycline, with a unique C7 moiety, interacts with bacterial ribosomes to block translation and prevent antibiotic resistance. Sarecycline reduces
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.